Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use

被引:0
|
作者
Holvoet, C
Vander Heyden, Y
Plaizier-Vercammen, J
机构
[1] Vrije Univ Brussels, Dept Pharmaceut Technol & Phys Pharm, B-1090 Brussels, Belgium
[2] Vrije Univ Brussels, Dept Pharmaceut & Biomed Anal, B-1090 Brussels, Belgium
来源
PHARMAZIE | 2005年 / 60卷 / 08期
关键词
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A parenteral formulation for the water-insoluble benzodiazepine diazepam was developed. Different cyclodextrins (CDs) suitable for parenteral injection: hydroxypropyl-beta-cyclodextrin (HP-beta-CD), hydroxypropyl-gamma-cyclodextrin (HP-gamma-CD), sulfobutylether-7-beta-cyclodextrin (SBE-7-beta-CD) and maltosyl-beta-cyclodextrin (malt-beta-CD) were used as alternatives to cosolvents to increase solubility. The increase in solubility displayed a concentration dependency for the four CDs used. Diazepam's solubility is enhanced linearly as a function of each CD concentration. The highest improvements in solubility (dissolved concentration circa 3.5 mg/ml in 40% CD) were found by adding HP-beta-CD or SBE-beta-P-CD. The additional use of polyvinylpyrrolidone (PVP) did not further increase the solubility of diazepam with HP-beta-CD. A parenteral aqueous diazepam solution was prepared containing 10 mg diazepam/5 ml 30% HP-beta-CD or SBE-7-beta-CD solution. The preparations are in agreement with the requirements for parenteralia. Sterilisation by filtration is required since autoclaving degrades the active compound. The stability of the preparations, with and without pH adjustment to pH 5, was investigated during 18 months and during this period no noticeable degradation was observed.
引用
收藏
页码:598 / 603
页数:6
相关论文
共 50 条
  • [1] Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use
    Holvoet, C
    Vander Heyden, Y
    Plaizier-Vercammen, J
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (06) : 567 - 575
  • [2] THE POTENTIAL USE OF CYCLODEXTRINS IN PARENTERAL FORMULATIONS
    BREWSTER, ME
    SIMPKINS, JW
    HORA, MS
    STERN, WC
    BODOR, N
    JOURNAL OF PARENTERAL SCIENCE AND TECHNOLOGY, 1989, 43 (05): : 231 - 240
  • [3] Cyclodextrins in Parenteral Formulations
    Loftsson, Thorsteinn
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (02) : 654 - 664
  • [4] Inclusion complexation with cyclodextrins
    Klein, CT
    Viernstein, H
    Wolschann, P
    MINERVA BIOTECNOLOGICA, 2000, 12 (04) : 287 - 292
  • [5] Inclusion complexation of glisentide with α-, β- and γ-cyclodextrins
    Zornoza, A
    Martín, C
    Sánchez, M
    Vélaz, I
    Piquer, A
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 169 (02) : 239 - 244
  • [6] Inclusion complexation of artemisinin with α-, β-, and γ-cyclodextrins
    Wong, JW
    Yuen, KH
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (09) : 1035 - 1044
  • [7] Inclusion complexation of nimesulide with β-cyclodextrins
    Vavia, PR
    Adhage, NA
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) : 543 - 545
  • [8] DEVELOPMENT OF AQUEOUS PARENTERAL FORMULATIONS FOR CARBAMAZEPINE THROUGH THE USE OF MODIFIED CYCLODEXTRINS
    BREWSTER, ME
    ANDERSON, WR
    ESTES, KS
    BODOR, N
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (04) : 380 - 383
  • [9] Inclusion Complexation Behaviors of Favipiravir into Cyclodextrins
    Kudo, Kanade
    Takata, Riko
    Yamasaki, Kaito
    Osaka, Issey
    Nakajima, Noriyuki
    Hamada, Masahiro
    Koyama, Yasuhito
    CHEMISTRY LETTERS, 2022, 51 (05) : 518 - 521
  • [10] INCLUSION COMPLEXATION OF DOXORUBICIN AND DAUNORUBICIN WITH CYCLODEXTRINS
    BEKERS, O
    BEIJNEN, JH
    OTAGIRI, M
    BULT, A
    UNDERBERG, WJM
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) : 671 - 674